Uncategorized
FDA panel endorses drug for vitreomacular adhesion
WASHINGTON (Reuters) - A Food and Drug Administration panel on Thursday recommended ThromboGenics NV's
ocriplasmin as a treatment for vitreomacular adhesion, an aging-related vision problem that can lead to
blindness.